GAD1 and type 2 diabetes mellitus: The recent guideline from the AACE stated that CSII may be suitable for selected T2D patients with suboptimal glucose control and a detectable C-peptide plasma concentration.24 Another recent guideline from the ADA/EASD stated that pump therapy may be an option in T2D patients with latent autoimmune diabetes of adulthood (LADA).4 The OPT2MISE trial provided an opportunity to evaluate the influence of C-peptide level and the presence of anti-glutamic acid decarboxylase (anti-GAD) antibodies detection in the OPT2MISE cohort.